Amiodarone-induced multiple organ damage in an Alström syndrome patient with end-stage renal disease and hepatic cirrhosis

Takuto Torimitsu, Tadashi Yoshida, Satomi Makiuchi, Hiroshi Itoh, Mototsugu Oya

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Alström syndrome (AS) is an extremely rare disease accompanied by blindness, hearing loss, obesity, type 2 diabetes, dilated cardiomyopathy, and progressive hepatic and renal dysfunction. The life span of AS patients rarely exceeds 50 years, and thus there are very few reports describing the implementation of renal replacement therapy for these patients. We here report a case of AS patient who exhibited dilated cardiomyopathy, end-stage renal disease, and hepatic cirrhosis. He underwent hemodialysis therapy more than 3 years. Although he eventually died of amiodarone-induced multiple organ damage in the lungs and liver, the present case suggests that hemodialysis therapy can be a choice of renal replacement therapy for AS patients with end-stage renal disease.

Original languageEnglish
Pages (from-to)11-16
Number of pages6
JournalCEN case reports
Volume11
Issue number1
DOIs
Publication statusPublished - 2022 Feb 1

Keywords

  • Amiodarone
  • End-stage renal disease
  • Hepatic cirrhosis
  • Hereditary kidney disease

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Amiodarone-induced multiple organ damage in an Alström syndrome patient with end-stage renal disease and hepatic cirrhosis'. Together they form a unique fingerprint.

Cite this